Table 2. PET/CT imaging and interpretation methods.
| Study reference | Post injection interval (min) |
FDG dose (MBq/kg) |
parameters | Cut-off values | Interpreters | Time interval before I-PET | Time interval before E-PET | ||
|---|---|---|---|---|---|---|---|---|---|
| SUVmax | MTV (mL) | TLG (g) | |||||||
| Jiang et al, 2017 [21] | 60 | 5.18 | E-PET/CT DS | 2 physicians specializing in nuclear medicine | During the 4 weeks after initial treatment | 3 weeks after the end of treatment |
|||
| Chang et al, 2017 [22] | 60±15 | 3.7–4.4 | B-PET/CT SUVmax, MTV and TLG | 15.1 | 16.1 | 44.7 | 2 experienced nuclear medicine physicians | Median 19.0 days (after 2–4 cycles of chemotherapy) | Median 31.5 days |
| Liang et al, 2016 [23] | 60 | 3.70–5.55 | B-PET/CT SUVmax | 15.8 | NR | NR | NR | ||
| Lim et al, 2016 [24] | NR | NR | I-PET/CT DS | 1 nuclear medicine physician | NR | NR | |||
| Jiang et al, 2015 [25] | 60 | 5.18 | I-PET/CT DS | 2 physicians specializing in nuclear medicine | 3 weeks (after 2 cycles of therapy) | NR | |||
| Kim et al, 2015 [26] | 60±10 | 5.5 | E-PET/CT DS | 1 experienced nuclear medicine physician | NR | At least 4 weeks after treatment | |||
| Kim et al, 2013 [27] | 60 | 8.1 | B-PET/CT SUVmax, MTV and TLG | 8.1 | 14.4 | 52.7 | NR | NR | NR |
| Bai et al, 2013 [28] | 60 | 4.4 | B-PET/CT SUVmax | 15 | 2 experienced nuclear medicine physicians | NR | NR | ||
| Song et al, 2013 [29] | NR | NR | B-PET/CT MTV | 35.2 | 1 nuclear medicine expert | NR | NR | ||
NR, not reported.